Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

Executive Summary

FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.

You may also be interested in...



NIH Funding Boost Underscores Tensions Between Trump, Congress

Onmibus funding bill would increase NIH funding by $2 billion, including $120 million increase for Precision Medicine Initiative; antibiotic resistance and Alzheimer's research also slated for increase.

Antibiotic Development: Limited Population Pathway In US Removes Barrier

Allergan's Avycaz could be indicator of how FDA will use the 21st Century Cure's new approval mechanism; experts maintain the provision does not lower FDA's standards of safety.

US FDA Advisory Committee Drought Is Over … Unless Sponsors Are Scared Of Dark Clouds

FDA has three NDAs set for public advisory committee review at the end of March and early April, the first 'real' committee meetings in five months. Oops. Make that two.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS119467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel